A Two-Part Study of ZX008 in Children and Adults With Lennox-Gastaut Syndrome (LGS); Part 1: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo Controlled Trial of Two Fixed Doses of ZX008 (Fenfluramine Hydrochloride) Oral Solution as Adjunctive Therapy for Seizures in Children and Adults With LGS, Followed by Part 2: An Open-Label Extension Trial to Assess Long-Term Safety of ZX008 in Children and Adults With LGS

Trial Profile

A Two-Part Study of ZX008 in Children and Adults With Lennox-Gastaut Syndrome (LGS); Part 1: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo Controlled Trial of Two Fixed Doses of ZX008 (Fenfluramine Hydrochloride) Oral Solution as Adjunctive Therapy for Seizures in Children and Adults With LGS, Followed by Part 2: An Open-Label Extension Trial to Assess Long-Term Safety of ZX008 in Children and Adults With LGS

Recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Dec 2017

At a glance

  • Drugs Fenfluramine (Primary)
  • Indications Lennox-Gastaut syndrome
  • Focus Therapeutic Use
  • Sponsors Zogenix
  • Most Recent Events

    • 29 Nov 2017 Status changed from not yet recruiting to recruiting, according to a Zogenix media release.
    • 29 Nov 2017 According to a Zogenix media release, Kelly Knupp from Childrens Hospital Colorado is the Principal Investigator of the U.S. arm of the trial.
    • 29 Nov 2017 According to a Zogenix media release, first patient has been enrolled.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top